TCGA-AO-A125-01A-11R-A10J-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 115
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.230
- ESTROGEN_RESPONSE_LATE+0.190
- OXIDATIVE_PHOSPHORYLATION+0.100
- HEME_METABOLISM+0.090
- FATTY_ACID_METABOLISM+0.080
- DNA_REPAIR+0.060
- GLYCOLYSIS+0.000
- PEROXISOME+0.000
- P53_PATHWAY-0.020
- SPERMATOGENESIS-0.020
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.530
- INTERFERON_GAMMA_RESPONSE-0.430
- MYC_TARGETS_V2-0.430
- IL6_JAK_STAT3_SIGNALING-0.410
- INFLAMMATORY_RESPONSE-0.400
- ANGIOGENESIS-0.390
- E2F_TARGETS-0.380
- MITOTIC_SPINDLE-0.380
- COMPLEMENT-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A1B4-01A-11R-A12P-07 | — | B | 0.885 |
| 2 | TCGA-BH-A0HN-01A-11R-A10U-07 | — | B | 0.871 |
| 3 | 308a5759-8930-433f-8d11-4c3da6ed0e29 | — | — | 0.867 |
| 4 | SRR25617889 | — | B | 0.860 |
| 5 | eb67b977-b299-4bbc-b3f6-25d516473405 | — | — | 0.838 |
| 6 | SRR2016961 | — | — | 0.836 |
| 7 | TCGA-E2-A2P6-01A-11R-A19W-07 | — | B | 0.834 |
| 8 | TCGA-AO-A12H-01A-11R-A115-07 | — | B | 0.833 |
| 9 | TCGA-BH-A8FY-01A-11R-A36F-07 | — | B | 0.832 |
| 10 | TCGA-E2-A15G-01A-11R-A12D-07 | — | B | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |